Novartis and Molecular Partners’ Ensovibep Flunks In ACTIV-3 In Hospitalized COVID-19 Patients

Hopes Turn To Non-Hospitalized Patients

 
• By Ayisha Sharma
Ensovibep Was Administered Intravenously In The ACTIV-3 Trial • Source: Alamy

More from Clinical Trials

More from R&D